Summer Street shrugs off Intercept Pharma LDL concerns


Shares of Intercept Pharmaceuticals (ICPT -20.5%) are off their premarket lows, but are still sharply lower coming off last week's improbable run.

Count Summer Street's Bart Classen among those not too concerned with the "bad" cholesterol chatter that's at least partly responsible for today's sell-off.

Classen reportedly thinks that due to the seriousness of NASH, a potential rise in LDL likely won't be enough to deter many people from using OCA.

From other sites
Comments (2)
  • Leonard Yaffe
    , contributor
    Comments (168) | Send Message
     
    I am concerned both with the cholesterol increase as well as the very promising, but biopsy-based NAFLD Activity Score, results. NASH is prevalent, but is typically asymptomatic, taking decades to progress to cirrhosis. I would suggest not entertaining a long position a the current time. Len
    14 Jan 2014, 11:29 AM Reply Like
  • EatGreen
    , contributor
    Comments (6) | Send Message
     
    Long way to success. Once it does then it will make more sense for the PT suggested. Crazy investors, crazy results. Lawsuit pending already...I won't be surprise two months from we'll be in the sub $100 / share...likely $80.
    15 Jan 2014, 04:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs